The purpose of this study is to test any good and bad effects of the study drug 131I-omburtamab. 131I-omburtamab could prevent the cancer from returning, or delay the cancer from getting worse, but it could also cause side effects. Researchers hope to learn more about how 131I-omburtamab works in the body, and how effective it is in treating cancer. 131I-Omburtamab is not approved by the FDA to treat DSRCT or other cancers of the peritoneum.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
31
Single dose of IP RIT administered through an IP catheter with 131 I-omburtamab at 80mCi/m2
Group A participants will receive WAP-IMRT approximately 2-4 weeks after completing IP RIT. A dose of 30 Gy will be delivered in 20 fractions of 1.5 Gy given once daily, 5 days per week over the course of approximately 4 weeks
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Progression Free Survival/PFS
Progression free survival after RIT + WA-IMRT.
Time frame: Up to 2 years after treatment is discontinued
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.